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Abstract (193)   
The purpose of this study was to create novel urate under-excretion animal models 
using pyrazinamide and to evaluate whether dihydropyridine calcium channel blockers 
(CCBs) have uricosuric effects in vivo.  
Adult male ICR mice were treated with pyrazinamide, vehicle (DMSO), or tap water. 
Thirty minutes later, pyrazinamide-trearted mice were given benzbromarone, losartan, 
nilvadipine, nitrendipine, nifedipine or azelnidipine. Six hours after the second 
administration, urine (by urinary bladder puncture) and plasma were collected to 
measure uric acid and creatinine levels, and fractional excretion of uric acid (FEUA) 
and creatinine clearance (Ccr) were calculated and evaluated. There was no significant 
difference in the levels of plasma uric acid, plasma creatinine, Ccr, urinary 
N-acetyl-β-D-glucosaminidase (NAG) and urinary NAG-creatinine ratio between water, 
DMSO, and pyrazinamide-treated mice. But the FEUA of pyrazinamide-treated mice 
was significantly lower than water mice. The FEUA was significantly higher in mice 
taking the dihydropyridine CCBs (nilvadipine, nitrendipine, nifedipine, and high-dose 
azelnidipine) than in pyrazinamide-treated mice. There was no significant difference in 
Ccr. 
Thus, a novel animal model created with PZA administration was useful as a urate 
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under-excretion animal model that was probably URAT1-mediated, and the uricosuric 
effect of dihydropyridine CCBs was confirmed in vivo. 
 
Keywords: uric acid, urate, fractional excretion of uric acid, urate under-excretion 
animal model, calcium channel blocker 
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Introduction 
In humans, serum uric acid levels are determined by the balance between 
enzymatic production mainly in the liver by xanthine oxidase and urinary excretion 
mediated by renal tubular urate transporters [1]. Renal excretion of urate corresponds to 
60–70% of total urate excretion from the human body [2, 3]. Human urate transporter 1 
(URAT1; SLC22A12) was first identified in 2002 [4]. URAT1 exchanges urate and 
monocarboxylates in the molecular mechanism of urate reabsorption. Later, several 
transporters, such as sodium phosphate transporter 4 (SLC17A3) and glucose transporter 
9/voltage-driven urate transporter 1 (SLC2A9), were found to be closely associated with 
reabsorption and excretion of urate [5-7]. It has been reported that hyperuricemia is 
often associated with hypertension and high mortality [8]. The causes of hyperuricemia 
are urate over-production, urate under-excretion, and combined type. The hyperuricemia 
induced by urate under-excretion should be treated with uricosuric drugs, and the 
pharmacological action target of these drugs is URAT1.  
In the Japanese guideline for the management of hyperuricemia and gout, it is 
noted that losartan and calcium channel blockers (CCBs) have urate-lowering effects, 
thus decreasing serum uric acid levels [9]. Losartan is one of the angiotensin II  
receptor blockers, and the molecular mechanism of the urate-lowering effect of losartan 
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has been reported to be inhibition of URAT1 and increased excretion of urate in the 
urine [10]. CCBs are common anti-hypertensive drugs that inhibit calcium entry by 
interacting with voltage-gated calcium channels [11]. Several clinical studies have 
shown that CCBs have uricosuric actions [12, 13]. In previous studies, it has been 
reported that CCBs, especially the dihydropyridine group, have uricosuric effects in rats, 
and the effect was considered to be induced by increases of renal blood flow and the 
glomerular filtration rate [14]. Recently, we reported that the urate-lowering effect of 
CCBs, especially the dihydropyridine group, may be associated with inhibition of renal 
urate reabsorption mediated by renal urate transporters such as URAT1 [15]. 
Nevertheless, little is known about the molecular mechanism of the urate-lowering 
effect of CCBs.  
Oxonate-treated mice known as an animal model for hyperuricemia are injected 
intraperitoneally with the uricase inhibitor potassium oxonate [16]. We thought that this 
hyperuricemia animal model is not appropriate for evaluating the uricosuric action with 
URAT1 because hyperuricemia in this animal model is induced by the inhibition of the 
uricase enzyme that oxidizes uric acid to allantoin. A urate under-excretion animal 
model is needed to evaluate the uricosuric action with URAT1 and other urate 
transporters, but there was no appropriate animal model. 
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Pyrazinamide (pyrazine-2-carboxamide) is a well-known antituberculosis drug, and it 
was previously reported that pyrazinamide induces hyperuricemia as a side effect in 
clinical use [17, 18]. URAT1 mediates the exchange of urate for several organic anions, 
inorganic anions, and monocarboxylic acids such as 2-pyrazinoic acid [4]. After taking 
pyrazinamide, it is presumed that pyrazinamide is converted into pyrazinoic acid, and 
5-hydroxypyrazinoic acid in the body [19, 20]. These substrates are monocarboxylic 
acids. The major pathway of pyrazinamide metabolism is from pyrazinamide to these 
substrates, which are the excretory products [21]. In the kidney, the main excretion 
pathway of pyrazinamide is glomerular filtration [21]. 
The purpose of this study was to create novel animal models using pyrazinamide and 
to evaluate whether dihydropyridine CCBs have uricosuric effects in vivo. 
 
Materials and Methods 
Animals 
Adult male ICR mice were obtained from CLEA Japan, Inc. (Tokyo, Japan) and 
used in the present study. Eleven-week-old mice were used in each experiment; their 
body weights were 40.4 ± 0.2 g. All mice were supplied with a commercial diet (MF; 
Oriental Yeast Co., Ltd., Tokyo, Japan) and water ad libitum. The animals were housed 
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under controlled temperature and light conditions (lights on from 7:00 to 19:00). The 
experimental protocols were approved by the Animal Care and Use Committee, and 
experiments were carried out according to the Guidelines for Animal Experimentation 
of Dokkyo Medical University. All efforts were made to minimize the number of 
animals used and their suffering. 
 
Experimental protocols 
Pyrazinamide was obtained from Sigma-Aldrich Co., LLC. (Saint Louis, MO, USA). 
Benzbromarone, nitrendipine, nifedipine, and dimethyl sulfoxide (DMSO) were 
obtained from Wako Pure Chemical Industry Ltd. (Osaka, Japan). Nilvadipine and 
azelnidipine were purchased from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan). L 
osartan was purchased from Merck & Co. (Kenilworth, NJ, USA). All agents,  
including pyrazinamide, were dissolved in DMSO and administered per os to mice 
using a cannula at an injection volume of 2.5 ml/kg body weight. Mice were 
anesthetized with isoflurane (Pfizer Japan Inc., Tokyo, Japan) and treated with 
pyrazinamide (400 mg/kg), vehicle, or tap water.  
Previous studies investigated rats treated with losartan (3.0 mg/kg, per os) by oral 
gavage [22], and described mice treated with losartan (3.0 mg/kg) that was dissolved in 
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drinking water for consumption [23]. Based on these reports, an losartan dose of 3.0 
mg/kg was first selected for the present study. A previous in vivo study showed the 
effects of nilvadipine on the cardiovascular system [24]. In the previous study, the doses 
of nilvadipine used were 1.0 or 3.2 mg/kg in rats. Accordingly, both nilvadipine 
concentrations (1.0 and 3.2 mg/kg, per os) were used in the present study. Based on the 
above information, 3.2 mg/kg doses of nitrendipine, nifedipine, and azelnidipine were 
selected. However, azelnidipine (3.2 mg/kg) failed to give a clear result. In regard to 
azernidipine, high-dose azelnidipine (10.0 mg/kg) was selected in the present study. 
Protocol is shown in Supplemental figure. Thirty minutes after the first administration 
(pyrazinamide 400 mg/kg), mice were additionally treated with benzbromarone (3.0 or 
10.0 mg/kg), losartan (3.0 mg/kg), nilvadipine (1.0 or 3.2 mg/kg), nitrendipine (3.2 
mg/kg), nifedipine (3.2 mg/kg), or azelnidipine (10.0 mg/kg [high-dose azelnidipine]). 
The mice after voiding were placed individually in metabolic cages (KN-645; Natsume 
Seisakusho Co., Ltd., Tokyo, Japan) to collect urine for six hours. Six hours after the 
second administration, the mice were anesthetized with isoflurane. Then urine samples 
were collected by urinary bladder puncture, and blood samples were obtained from the 
inferior vena cava. The mice were euthanized by bleeding from the inferior vena cava 
under deep anesthesia. The blood was collected in heparinized sampling tubes, and it 
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was centrifuged to obtain the plasma for the determination of uric acid and creatinine 
levels. The collected urine from metabolic cage and urinary bladder puncture were 
combined as total urine volume (UV). 
 
Quantitative determinations of uric acid and creatinine levels, urinary markers of 
tubular damage 
To measure uric acid levels in plasma (Pua) and urine (Uua), the spectrophotometric 
method combined with measurement of total antioxidative capacity by ferric reducing 
anti oxidative power (FRAP) assay with the uricase-reaction (specific elimination of 
urate) was used [25]. In this method, uric acid levels were calculated from FRAP values. 
Uricase was obtained from Oriental Yeast Co., Ltd. The QuantiChrom™ Creatinine 
Assay Kit (BioAssay Systems, Hayward, CA, USA) was used to measure the creatinine 
levels (mg/dl) in plasma (Pcr) and urine (Ucr). 
Urinary N-acetyl-β-D-glucosaminidase (NAG) and urinary β2 microglobulin were 
measured as the marker of tubular damage. Urinary NAG was determined by 
colorimetric method (BML, Inc., Japan). Urinary β2 microglobulin was determined by 
latex coagulation method (BML, Inc., Japan). Urinary creatinine has been used to adjust 
for urinary NAG in many reports. Recently, we have also reported clinical research with 
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using urinary NAG / urinary creatinine levels in human [26, 27]. According to the above, 
we showed urinary NAG, and urinary NAG / urinary creatinine in the present study. 
 
Fractional excretion of uric acid and creatinine clearance 
Fractional excretion of uric acid (FEUA) was calculated from Pua, Uua, Pcr, and Ucr. 
Creatinine clearance (Ccr) was calculated from Ucr, Pcr, and UV (ml/min/kg). There are 
reports using Ccr in rats, which units composed from urine volume, time, and body 
weight [28,29]. This same units have been also used in mouse as well [30]. According to 
the above, we showed Ccr in the present study. 
 
FEUA (%) = (Uua × Pcr ×100) / (Pua × Ucr) 
Ccr (ml/min/kg) = (UV × Ucr) / Pcr 
 
Statistical analysis 
Statistical tests were performed using JMP (version 11.2.0; SAS Institute Inc., Cary, 
NC, USA). The statistical method was assessed by the Fisher’s least significant 
difference test. P-values less than 0.05 were considered significant. Firstly, significant 
differences were determined using one-way analysis of variance (ANOVA). When there 
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was a significant difference among groups by using ANOVA, followed by Student’s 
t-tests were performed between pyrazinamide group and other drug (benzbromarone and 
antihypertensive drugs) group. All data are presented as means ± SE.   
 
Results  
Creation of renal urate underexcretion mice  
The results for Pua, Pcr, Urinary NAG, and Urinary NAG-creatinine ratio of the 
Water group, DMSO first (DMSO-1) group, and pyrazinamide first (pyrazinamide-1) 
group (n = 8, 6, and 6, respectively) are shown in Table 1. One specimen for urinary 
NAG and urinary NAG-creatinine ratio was failed to obtain, because the amount of the 
specimen was insufficient. There was no significant difference in Pua, Pcr, urinary NAG, 
and urinary NAG-creatinine ratio. The results for FEUA and Ccr of the Water, DMSO, 
and pyrazinamide-1 groups are shown in Figure 1 (n = 8, 6, and 6, respectively). FEUA 
(%) was 16.44 ± 2.26 (Water group), 12.87 ± 3.92 (DMSO-1 group), and 2.61 ± 0.74 
(pyrazinamide-1 group) (Figure 1A). There was a significant difference in FEUA among 
the 3 groups (p = 0.004). There was no significant difference in FEUA between the 
Water group and the DMSO-1 group (p = 0.453), but FEUA was significantly lower in 
the pyrazinamide-1 group than in the Water group (p < 0.001) and the DMSO-1 group 
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(p = 0.047). Ccr (ml/min/kg) was 8.19 ± 0.84 (Water group), 7.28 ± 1.17 (DMSO group), 
and 8.21 ± 1.51 (pyrazinamide-1 group) (Figure 1B). There was no significant 
difference in Ccr among the 3 groups (p = 0.820).  
 
Effects of benzbromarone, losartan, and nilvadipine 
Figure 2 shows FEUA and Ccr in the pyrazinamide second (pyrazinamide-2) group, 
administered with benzbromarone 3.0 mg/kg (benzbromarone3.0) group, administered 
with benzbromarone 10.0 mg/kg (benzbromarone10.0) group, and administered with 
losartan 3.0 mg/kg (losartan3.0) group (n = 5, 6, 5, and 8, respectively).  
FEUA (%) was 3.90 ± 1.32 (pyrazinamide-2 group), 4.90 ± 0.70 (benzbromarone3.0 
group), 16.40 ± 3.44 (benzbromarone10.0 group), and 13.04 ± 2.63 (losartan3.0 group) 
(Figure 2A). There was a significant difference in FEUA among the 4 groups (p = 
0.004). FEUA was higher in the benzbromarone3.0 group than in the pyrazinamide-2 
group, though no significant difference was seen between the two groups (p = 0.529). 
FEUA was significantly higher in the benzbromarone10.0 group than in the 
pyrazinamide-2 group (p = 0.019). FEUA was significantly higher in the losartan3.0 
group than in the pyrazinamide-2 group (p = 0.011). Ccr (ml/min/kg) was 7.94 ± 0.99 
(pyrazinamide-2 group), 9.12 ± 1.20 (benzbromarone3.0 group), 10.10 ± 1.74 
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(benzbromarone10.0 group), and 7.80 ± 0.82 (losartan3.0 group) (Figure 2B). There 
was no significant difference in Ccr among the 4 groups (p = 0.487).  
Figure 3 shows the results for FEUA and Ccr in the pyrazinamide third 
(pyrazinamide-3) group, administered with nilvadipine 1.0 mg/kg (nilvadipine1.0) 
group, and administered with nilvadipine 3.2 mg/kg (nilvadipine3.2) group (n = 6, 9, 
and 9, respectively). FEUA (%) was 3.67 ± 0.83 (pyrazinamide-3 group), 6.46 ± 0.92 
(nilvadipine1.0 group), and 7.29±0.87 (nilvadipine3.2 group) (Figure 3A). There was a 
significant difference in FEUA among the 3 groups (p = 0.040). FEUA was significantly 
higher in the nilvadipine1.0 group and the nilvadipine3.2 group than in the 
pyrazinamide-3 group (p = 0.043 [nilvadipine1.0 group], 0.011 [nilvadipine3.2 group]). 
FEUA was higher in the nilvadipine3.2 group than in the nilvadipine1.0 group, but there 
was no significant difference between them. Ccr (ml/min/kg) was 8.16 ± 0.99 
(pyrazinamide-3 group), 10.20 ± 1.51 (nilvadipine1.0 group), and 9.51 ± 1.33 
(nilvadipine3.2 group). There was no significant difference in Ccr among the 3 groups 
(p = 0.617). 
 
Effects of calcium channel blockers 
The results for FEUA and Ccr in the pyrazinamide fourth (pyrazinamide-4) group (n 
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= 6) and CCB groups are shown in Figure 4. The CCB groups were the administered 
with nitrendipine 3.2 mg/kg (nitrendipine3.2) group, administered with nifedipine 3.2 
mg/kg (nifedipine3.2) group, and administered with azelnidipine 10.0 mg/kg 
(azelnidipine10.0) group (n = 6, 8, 9, and 10, respectively). FEUA (%) was 2.93 ± 0.91 
(pyrazinamide-4 group), 7.21 ± 1.01 (nitrendipine3.2 group), 6.84 ± 1.21 (nifedipine3.2 
group), and 13.10 ± 2.33 (azelnidipine10.0 group) (Figure 4A). There was a significant 
difference among the 4 groups (p = 0.002). FEUA was significantly higher in the 
nitrendipine3.2, nifedipine3.2, and azelnidipine10.0 groups than in the pyrazinamide-4 
group (p = 0.008, 0.023, and 0.002 respectively). Ccr (ml/min/kg) was 7.70 ± 1.47 
(pyrazinamide-4 group), 7.69 ± 0.54 (nitrendipine3.2 group), 8.00 ± 0.68 (nifedipine3.2 
group), and 5.74 ± 1.05 (azelnidipine10.0 group) (Figure 4B). There was no significant 
difference in Ccr among the 4 groups (p = 0.265). 
 
Discussion 
In the present study, without a difference in Ccr between control mice and 
pyrazinamide-treated mice, FEUA was lower in pyrazinamide-treated mice than in 
control mice. In addition, FEUA was higher in mice taking nilvadipine, nitrendipine, 
nifedipine, and high-dose azelnidipine than in pyrazinamide-treated mice. There were 
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significant differences in FEUA between pyrazinamide-treated mice and mice taking 
CCBs (nilvadipine, nitrendipine, nifedipine, and high-dose azelnidipine).  
Figure 1 and Table 1 show that FEUA was lower in pyrazinamide-treated mice than 
in control mice, with no significant difference in Ccr, urinary NAG, and urinary 
NAG-creatinine ratio between the two groups. Urinary β2-microglobulin was also 
measured simultaneously as a marker of tubular damage in Water, DMSO-1, and PZA-1 
groups. The obtained measurement results of urinary β2-microglobulin were below the 
limit of detection (less than 0.3 mg/L) (Data not shown). Moreover, FEUA was higher 
in mice taking benzbromarone and losartan than in pyrazinamide-treated mice (Figure 
2). Benzbromarone is a uricosuric agent used in the treatment of hyperuricemia. As in 
rodent experiments, benzbromarone has been recently used [31]. It is known that 
benzbromarone and losartan inhibit urate uptake via URAT1 [4, 32]. Together, these 
results suggest that the pyrazinamide-treated mice are probably useful as a urate 
under-excretion animal model. Moreover, the present method is apparently simple and 
convenient. There was no significant difference in plasma uric acid levels between 
pyrazinamide-treated mice and control mice (Table 1). For this reason, the present 
model was not a hyperuricemic animal model, but rather a urate under-excretion animal 
model. Unfortunately, we only used one dose of pyrazinamide, and the plasma level of 
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uric acid did not change with this dose. It is not clear how the level of plasma uric acid 
changes when a higher pyrazinamide dose is used. Uricase in mice has complicated the 
interpretation of plasma uric aicd levels.  
We previously reported that the urate-lowering effect of CCBs may be associated 
with inhibition of renal urate reabsorption mediated by renal urate transporters such as 
URAT1 [15]. The degree of URAT1 inhibition by CCBs is probably related to their 
structural differences. In our previous in vitro findings, some of the dihydropyridine 
subgroup of CCBs inhibited URAT1, but the non-dihydropyridine subgroup did not. 
Based on our previous study, these 4 CCBs (nilvadipine, nitrendipine, nifedipine, and  
azelnidipine in the dihydropyridine subgroup) were selected for the present in vivo study. 
Nilvadipine was the strongest inhibitor of URAT1 of all of the CCBs investigated in our 
previous in vitro study. For this reason, whether nilvadipine has an inhibitory action of 
URAT1 was investigated first in the present study. The present study demonstrated that 
nilvadipine probably inhibits URAT1, and the same doses of nitrendipine and nifedipine 
also probably do. 
In our previous in vitro study, azelnidipine did not inhibit URAT1 [15]. However, 
the present study demonstrated that high-dose azelnidipine increased FEUA 
significantly. Clinically it has been reported that azelnidipine has a urate-lowering effect 
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[33]. Miyazaki et al. reported that azelnidipine decreased the serum uric acid level and 
blood pressure in patients with hyperuricemia and hypertension [33]. In the present 
study, the data of high-dose azelnidipine provides the interpretation of previous clinical 
study. 
Sodium-dependent monocarboxylate transporter 1 (SMCT1; SLC5A8) /2 (SMCT2; 
SLC5A12) is localized at the apical membrane in the renal proximal tubule, and it 
transport monocarboxylates such as lactate [32, 34, 35]. The proposed model of urate,  
monocarboxylic acid, and pyrazinamide metabolites transport via URAT1 and SMCT 
1/2 at the apical membrane in the proximal renal tubule is shown in Figure 5. Figure 5A 
shows that urate reabsorption is related with monocarboxylates and transporters in renal 
proximal tubule cells. First, monocarboxylates are cotransported with Na⁺  via 
SMCT1/2 from the lumen to the cell cytosol. Then, monocarboxylates and urate are 
exchange transported as the molecular mechanism of urate reabsorption. Figure 5B 
shows the molecular mechanism of urate reabsorption with administration of 
pyrazinamide. In the body, pyrazinamide is converted into pyrazinoic acid and 
5-hydroxypyrazinoic acid, which are excreted in urine. Urinary uric acid levels decrease, 
and this is probably the molecular mechanism of the side effect of hyperuricemia 
induced by pyrazinamide in humans [4]. In the present study, the plasma uric acid level 
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of mice did not change significantly with administration of pyrazinamide (Table 1). 
Mice have the uricase enzyme that oxidizes uric acid to allantoin. Therefore, the authors 
consider that the plasma uric acid level would not be increased in mice. Figure 5C 
shows the molecular mechanism of inhibition of URAT1 on proximal renal tubular cells 
induced by CCBs with administration of pyrazinamide. The pharmacological target of 
CCBs is URAT1, and they decreased the reabsorption of urate. As a result, the FEUAs 
of some CCBs were significantly higher than of pyrazinamide. 
Recently, it has been reported that various transporters are associated with urate 
excretion and reabsorption in the proximal tubules. Further experiments are needed to 
determine whether CCBs act on other urate transporters in vitro.  
In conclusion, the present study demonstrated that a novel animal model created 
with pyrazinamide administration was useful as a urate under-excretion animal model 
that was probably URAT1-mediated, and the uricosuric effect of dihydropyridine 
CCBs was confirmed in vivo. Thus, the advantage of the animal model is that it 
facilitates the quantitative pharmacological analysis of how urate excretion is affected 
by drugs. 
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Figure legends  
Figure 1. Effects of pyrazinamide on the fractional excretion of uric acid (FEUA) 
and creatinine clearance (Ccr) in mice 
Each group is comprised of 6 to 8 mice (Water group [No treatment], n = 8; DMSO-1 
group, n = 6; PZA-1 group, n = 6). (A), Fractional excretion of uric acid (FEUA) in the 
pyrazinamide treatment group. FEUA is significantly lower in the PZA-1 group than in 
the Water group (No treatment) and the DMSO-1 group (**p < 0.001 vs. Water group, 
#p < 0.05 vs. DMSO-1 group). (B), Creatinine clearance in the pyrazinamide treatment 
group. There was no significant difference in the Ccr levels among the 3 groups.  
FEUA, fractional excretion of uric acid; Ccr, creatinine clearance; DMSO, dimethyl 
sulfoxide; PZA, pyrazinamide. 
 
Figure 2. Effects of benzbromarone and losartan on the fractional excretion of uric 
acid (FEUA) and creatinine clearance (Ccr) in mice  
Each group is comprised of 5 to 8 mice (PZA-2 group, n = 5; BENZ3.0 group, n = 6; 
BENZ10.0 group, n = 5; LS3.0 group, n = 8). (A), Fractional excretion of uric acid 
(FEUA) in the benzbromarone and losartan groups. FEUA is significantly higher in the 
BENZ10.0 group and the LS3.0 group than in the PZA-2 group (*p < 0.05 vs. PZA-2 
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group). (B), Creatinine clearance in the benzbromarone and losartan groups. There was 
no significant difference in the Ccr levels among the 4 groups.  
FEUA, fractional excretion of uric acid; Ccr, creatinine clearance; DMSO, dimethyl 
sulfoxide; PZA, pyrazinamide; BENZ, benzbromarone; LS, losartan. 
 
Figure 3. Effects of nilvadipine on the fractional excretion of uric acid (FEUA) and 
creatinine clearance (Ccr) in mice  
Each group is comprised of 6 to 9 mice (PZA-3 group, n = 6; NV1.0 group, n = 9; 
NV3.2 group, n = 9).  
(A), Fractional excretion of uric acid (FEUA) in the nilvadipine groups. FEUA is 
significantly higher in the NV1.0 group and the NV3.2 group than in the PZA-3 group 
(*p < 0.05 vs. PZA-3 group). (B), Creatinine clearance in the nilvadipine groups. There 
was no significant difference in the Ccr levels among the 3 groups.  
FEUA, fractional excretion of uric acid; Ccr, creatinine clearance; PZA, pyrazinamide; 
NV, nilvadipine. 
 
Figure 4. Effects of nitrendipine, nifedipine, and azelnidipine on the fractional 
excretion of uric acid (FEUA) and creatinine clearance (Ccr) in mice 
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Each group is comprised of 6 to 10 mice (PZA-4 group, n = 6; NT3.2 group, n = 8; 
NF3.2 group, n = 9; AZ10.0 group, n = 10). (A), Fractional excretion of uric acid 
(FEUA) in the nitrendipine, nifedipine, and azelnidipine groups. FEUA is significantly 
higher in the NT3.2, NF3.2, and AZ10.0 groups than in the PZA-4 group (*p < 0.05 vs. 
PZA-4 group). (B), Creatinine clearance in the nitrendipine, nifedipine, and azelnidipine 
groups. There was no significant difference in the Ccr levels among the 4 groups.  
CCBs, calcium channel blockers; FEUA, fractional excretion of uric acid; Ccr, 
creatinine clearance; PZA, pyrazinamide; NT, nitrendipine; NF, nifedipine; AZ, 
azelnidipine. 
 
Figure 5. Proposed model of urate and monocarboxylic acid transport in the 
proximal renal tubule  
(A), Urate reabsorption and transport of MCs in the proximal renal tubule. Under 
normal conditions, urate reabsorption and transport of MCs on the lumen side in the 
proximal renal tubule cell. Urate (tubular lumen) and MCs (cytosol) are exchanged via 
URAT1. Sodium and MCs cotransport via SMCT1/2. (B), Urate reabsorption and 
transport of PZA in the proximal renal tubule. PZA is converted into PA and 5-OHPA in 
the body. Administration of PZA promotes this exchange transport. (C), Urate 
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reabsorption and transport of PZA in the proximal renal tubule with administration of 
BENZ, LS, and CCBs (NV, NT, NF, and AZ). CCBs (NV, NT, NF, and AZ) probably 
inhibit URAT1, and urinary excretion of urate increases.  
UA, urate; CCBs, calcium channel blockers; MCs, monocarboxylic acids; Na, sodium; 
PZA, pyrazinamide; URAT1, urate transporter 1; SMCT, sodium-dependent 
monocarboxylate transporter; PA, pyrazinoic acid; 5-OHPA, 5-hydroxypyrazinoic acid; 
BENZ, benzbromarone; LS, losartan; NV, nilvadipine; NT, nitrendipine; NF, nifedipine; 
AZ, azernidipine. 
 
Supplemental figure. Protocols for the induction of urate under-excretion mice and 
its treatment (BENZ, LS, or CCBs).  
Eleven-week-old mice were randomly allocated to the Water, DMSO, PZA, and 
treatment (BENZ, LS, or CCBs [NV, NT, NF, or AZ]). DMSO, dimethyl sulfoxide; PZA, 
pyrazinamide; BENZ, benzbromarone; LS, losartan; CCBs, calcium channel blockers; 
NV, nilvadipine; NT, nitrendipine; NF, nifedipine; AZ, azelnidipine; p.o., per os. 
Table 1: Results of plasma uric acid levels and renal function. 
 
 Water group    DMSO-1 group  PZA-1 group P-value 
Plasma uric acid (Pua) 
 (mg/dL) 
1.17 ± 0.12 1.59 ± 0.23 1.55 ± 0.24 0.240 
Plasma creatinine (Pcr) 
(mg/dL) 
0.17 ± 0.01 0.23 ± 0.04 0.18 ± 0.02 0.237 
Urinary NAG  
(U/L) 
87 ± 18 125 ± 20 88 ± 19 0.347 
Urinary NAG–creatinine 
ratio (U/mg Cr) 
0.60 ± 0.12 0.69 ± 0.21 0.64 ± 0.12  0.919 
DMSO, dimethyl sulfoxide; PZA, pyrazinamide; NAG, N-acetyl-β-D-glucosaminidase. 
Table Click here to download Table Table 1 20171114.docx 
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